LISINOPRIL TABLET

Država: Kanada

Jezik: angleščina

Source: Health Canada

Aktivna sestavina:

LISINOPRIL (LISINOPRIL DIHYDRATE)

Dostopno od:

COBALT PHARMACEUTICALS COMPANY

Koda artikla:

C09AA03

INN (mednarodno ime):

LISINOPRIL

Odmerek:

5MG

Farmacevtska oblika:

TABLET

Sestava:

LISINOPRIL (LISINOPRIL DIHYDRATE) 5MG

Pot uporabe:

ORAL

Enote v paketu:

30/100/500

Tip zastaranja:

Prescription

Terapevtsko območje:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Povzetek izdelek:

Active ingredient group (AIG) number: 0121550003; AHFS:

Status dovoljenje:

CANCELLED PRE MARKET

Datum dovoljenje:

2017-09-01

Lastnosti izdelka

______________________________________________________________________________________________
_
_LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _
_Page 1 of 44 _
_ _
_ _
PRODUCT MONOGRAPH
PR
LISINOPRIL
Lisinopril Tablets, USP
5 mg, 10 mg and 20 mg
(of Lisinopril as Lisinopril Dihydrate)
Angiotensin Converting Enzyme Inhibitor
Cobalt Pharmaceuticals Company
6500 Kitimat Road
Mississauga, Ontario
Canada, L5N 2B8
CONTROL NUMBER: 172480
Date of Revision:
March 4, 2014
______________________________________________________________________________________________
_
_LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _
_Page 2 of 44 _
_ _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
5
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
11
DRUG INTERACTIONS
.........................................................................................................
17
DOSAGE AND ADMINISTRATION
.....................................................................................
20
OVERDOSAGE
.......................................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 23
STORAGE AND STABILITY
.................................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.........................